Prophylaxis Cuts Thromboembolic Events

(00:05:27) Elsevier Global Medical News, 2008 Dec 7, JS MacNeil

Dr. Giancarlo Agnelli is Professor of Internal Medicine, University of Perugia, Italy. Dr. J. Evan Sandler is Professor of Medicine and of Biochemistry and Molecular Biophysics, Washington University Medical School, St. Louis.

Dr. Agnelli discusses findings of the phase III PROTECHT trial, which showed a halving of thromboembolic events in ambulatory cancer patients who received prophylaxis with nadroparin, a low–molecular-weight heparin. Dr. Sadler comments on the implications of these findings, presented at ASH 2008. 

See related videos to:
ASH 2008

Related Links:

News Story: Prophylaxis Cuts Thromboembolic Events by Half in Ambulatory Cancer Patients »

Copyright © 2010 International Medical News Group
Subscribe Now »